Head and Neck Squamous Cell Carcinoma Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 39 studies associated with Head and Neck Squamous Cell Carcinoma.
Here is a small sampling of Head and Neck Squamous Cell Carcinoma studies by title:
- Molecular Crosstalk and Therapeutic Synergy: Tyrosine Kinase Inhibitors and Cannabidiol in Oral Cancer Treatment
- CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma
- DNA damage and cell death in human oral squamous cell carcinoma cells: The potential biological effects of cannabidiol
- The Effect of Cannabis Plant Extracts on Head and Neck Squamous Cell Carcinoma and the Quest for Cannabis-Based Personalized Therapy
- Apoptotic effect of β-pinene on oral squamous cell carcinoma as one of the major compounds from essential oil of medicinal plant Piper rivinoides Kunth
Components of the Head and Neck Squamous Cell Carcinoma Research Dashboard
- Dosing information available for Head and Neck Squamous Cell Carcinoma
- Chemotype guidance for treating Head and Neck Squamous Cell Carcinoma with cannabis
- Synopsis of cannabis research for Head and Neck Squamous Cell Carcinoma
- Individual study details for Head and Neck Squamous Cell Carcinoma
Ready to become a subscriber? Go to our PRICING page.
Head and Neck Squamous Cell Carcinoma Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 39 studies associated with Head and Neck Squamous Cell Carcinoma.
Here is a small sampling of Head and Neck Squamous Cell Carcinoma studies by title:
- Molecular Crosstalk and Therapeutic Synergy: Tyrosine Kinase Inhibitors and Cannabidiol in Oral Cancer Treatment
- CBD promotes antitumor activity by modulating tumor immune microenvironment in HPV associated head and neck squamous cell carcinoma
- DNA damage and cell death in human oral squamous cell carcinoma cells: The potential biological effects of cannabidiol
- The Effect of Cannabis Plant Extracts on Head and Neck Squamous Cell Carcinoma and the Quest for Cannabis-Based Personalized Therapy
- Apoptotic effect of β-pinene on oral squamous cell carcinoma as one of the major compounds from essential oil of medicinal plant Piper rivinoides Kunth
Components of the Head and Neck Squamous Cell Carcinoma Research Dashboard
- Dosing information available for Head and Neck Squamous Cell Carcinoma
- Chemotype guidance for treating Head and Neck Squamous Cell Carcinoma with cannabis
- Synopsis of cannabis research for Head and Neck Squamous Cell Carcinoma
- Individual study details for Head and Neck Squamous Cell Carcinoma
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Head and Neck Squamous Cell Carcinoma
Description of Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the most common cancers worldwide, with several hundred thousand new cases each year. It develops from the squamous cells that line the mouth, throat, and other parts of the head and neck.
HPV Connection: A significant proportion of cases are linked to infection with the human papillomavirus (HPV), especially HPV type 16. In oropharyngeal cancers (tonsils, base of tongue), HPV is now responsible for the majority of new cases. These HPV-positive cancers often occur in younger people and typically respond better to treatment than those caused by other factors.
Other Risk Factors
Tobacco use – smoking or chewing remains one of the strongest risk factors.
Alcohol consumption – heavy use greatly increases risk, especially combined with tobacco.
Betel quid chewing – common in South and Southeast Asia, strongly linked to oral cancers.
Poor oral hygiene and chronic irritation.
Occupational exposures such as wood dust or certain chemicals.
Radiation exposure to the head and neck.
High-risk sexual behaviors that increase HPV transmission.
Who Is Affected: HNSCC is more common in men than women. Traditionally, it was seen in older individuals with long-term tobacco and alcohol exposure, but the rise of HPV-related disease is shifting the pattern to include younger, otherwise healthy people.
Treatment Approaches: Treatment depends on the tumor’s site and stage, but often includes:
Surgery to remove the tumor.
Radiation therapy to target residual disease.
Chemotherapy combined with radiation for advanced cases.
Immunotherapy (such as checkpoint inhibitors) is increasingly used for recurrent or metastatic disease.
Prognosis: HPV-positive cancers usually have a more favorable outlook than HPV-negative ones. Nonetheless, all forms of HNSCC can be serious, requiring careful treatment and long-term follow-up.
Disease Classification
Condition: Cancer - Squamous Head/NeckDisease Family: Cancer
Organ System: Integumentary System
ICD-10 Chapter: Neoplasms
ICD-10 Code: C44.42
Head and Neck Squamous Cell Carcinoma Symptoms:
Lump in neck, neck pain, swelling, difficulty swallowing or breathing, changes in voice or hearing, chronic mouth ulcers, swollen lymph nodes in neck, bleeding in mouth, nose, or throat, bad breath, ear pain. Symptoms are generally dependent on the anatomical location they appear in, as well as etiology.Also known as:
HNSCCDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
